Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study

Correlation of baseline biomarkers with clinical outcomes and response to fulvestrant with vandetanib or placebo in patients with bone predominant metastatic breast cancer: An OCOG ZAMBONEY sub-study

Background: Bone metastases are common in women with breast cancer and often result in skeletal related events (SREs). As the angiogenic factor vascular endothelial growth factor (VEGF) regulates osteoclast activity and is associated with more extensive bone metastases and SRE risk in metastatic bre...

Full description

Bibliographic Details
Main Authors: Christina L. Addison, Gregory R. Pond, Brandy Cochrane, Huijun Zhao, Stephen K. Chia, Mark N. Levine, Mark Clemons
Format: Article
Language:English
Published: Elsevier 2015-06-01
Series:Journal of Bone Oncology
Subjects:
Breast cancer
Bone metastasis
Vandetanib
Biomarker
Skeletal related event
Patient outcome
Online Access:http://www.sciencedirect.com/science/article/pii/S2212137415200231

Internet

http://www.sciencedirect.com/science/article/pii/S2212137415200231

Similar Items